Latest News

Chi-Med commences Phase I/II trial of HMPL-453 for solid tumours

Hutchison China MediTech (Chi-Med) has commenced a Phase I/II clinical trial of HMPL-453 in China for the treatment of solid tumours in patients carrying fibroblast growth factor receptor...

Chi-Med commences Phase I/II trial of HMPL-453 for solid tumours

Deals this week: Dova Pharmaceuticals Inc, Gamida Cell Ltd, Onxeo SA

US-based clinical-stage pharmaceutical company Dova Pharmaceuticals Inc is intending to raise between $60.93m and $69.06m through an initial public offering (IPO) of 4,062,500 shares of its...

Deals this week: Dova Pharmaceuticals Inc, Gamida Cell Ltd, Onxeo SA

Novartis reports positive top-line data from Phase III trial of cardiovascular drug

Novartis has reported positive top-line results from the Phase III CANTOS clinical trial of ACZ885 (canakinumab) and standard-of-care combination to address cardiovascular risk in patients...

Novartis reports positive top-line data from Phase III trial of cardiovascular drug

M&As this week: Shanghai ChemPartner Co, Cell Medica, BBI Group Holding

ShangPharma Corporation's contract research subsidiary Shanghai ChemPartner Co Ltd is set to merge with Quantum Hi-Tech (China) Biological Co...

M&As this week: Shanghai ChemPartner Co, Cell Medica, BBI Group Holding

CTD Holdings starts enrolment in Phase I/II trial of Trappsol Cyclo for NPC

CTD Holdings starts enrolment in Phase I/II trial of Trappsol Cyclo for NPC

Immune Pharma starts enrolment in Phase I/II trial of Ceplene for CMML

Immune Pharma starts enrolment in Phase I/II trial of Ceplene for CMML

InDex initiates enrolment for Phase IIb trial of cobitolimod to treat ulcerative colitis

Sweden-based InDex Pharmaceuticals has started patient enrolment in Phase IIb CONDUCT clinical trial of cobitolimod for treatment of patients with ulcerative...

InDex initiates enrolment for Phase IIb trial of cobitolimod to treat ulcerative colitis

New Phase I/II trial indicates positive outcome for Astellas' cancer drug

US researchers at the University of Pennsylvania’s (Penn) Perelman School of Medicine and Abramson Cancer Centre have reported positive data from a Phase I/II clinical trial of...

New Phase I/II trial indicates positive outcome for Astellas' cancer drug

Hansa Medical begins IdeS dosing in Phase II trial for anti-GBM antibody disease

Swedish biopharmaceutical firm Hansa Medical has begun dosing patients in its Phase II clinical trial of drug candidate IgG degrading enzyme of Streptococcus pyogenes (IdeS), to treat patients...

Hansa Medical begins IdeS dosing in Phase II trial for anti-GBM antibody disease

Effector, Pfizer and Merck to initiate Phase II combination trial for colorectal cancer

Effector Therapeutics has signed a clinical collaboration and supply agreement with Pfizer and Merck to initiate a Phase II clinical trial of immuno-oncology drugs combination to...

Effector, Pfizer and Merck to initiate Phase II combination trial for colorectal cancer

Genexine to conduct Phase Ib/II combination trial of cervical cancer drug GX-188E

Biotechnology firm Genexine has secured approval from the South Korean Ministry of Food and Drug Safety (MFDS) to conduct a Phase Ib/II trial of GX-188E vaccine in combination with...

Genexine to conduct Phase Ib/II combination trial of cervical cancer drug GX-188E

Seattle Genetics stops Phase III trial of leukaemia drug due to high death rate

Seattle Genetics stops Phase III trial of leukaemia drug due to high death rate

GSK’s Benlysta shows positive outcome in Phase II continuation trial for SLE

GlaxoSmithKline (GSK) reported positive data from the Phase II ten-year continuation clinical trial of Benlysta (belimumab) in combination with standard-of-care for patients suffering from...

GSK’s Benlysta shows positive outcome in Phase II continuation trial for SLE

Synlogic begins dosing in Phase I trial of SYNB1020 to treat hyperammonemia

Synlogic has begun dosing healthy volunteers in its Phase I clinical trial of SYNB1020 for the treatment of hyperammonemia associated with diseases such as urea cycle disorders (UCD) and...

Synlogic begins dosing in Phase I trial of SYNB1020 to treat hyperammonemia

Galera enrols last patient in Phase IIb trial of GC4419 to treat oral mucositis

US-based biotechnology company Galera Therapeutics has concluded enrolment in the Phase IIb clinical trial of GC4419 for the treatment of oral mucositis (OM) in patients with head and neck...

Galera enrols last patient in Phase IIb trial of GC4419 to treat oral mucositis

Novartis reports favourable data from Phase III extension trial of Cosentyx for AS

Novartis reports favourable data from Phase III extension trial of Cosentyx for AS

Xencor reports interim positive results from Phase II trial of XmAb5871 for IgG4-RD

Biopharmaceutical firm Xencor has reported interim positive results from the Phase II clinical trial of XmAb5871 for the treatment of patients with active IgG4-Related Disease...

Xencor reports interim positive results from Phase II trial of XmAb5871 for IgG4-RD

Helsinn and MEI begin dosing in Phase II combination trial to treat MDS

Swiss pharmaceutical group Helsinn and US-based oncology firm MEI Pharma have begun dosing patients in a Phase II clinical trial of pracinostat and azacitidine combination for the treatment...

Helsinn and MEI begin dosing in Phase II combination trial to treat MDS

RedHill Biopharma commences Phase III trial of RHB-105 to treat H. pylori infection

RedHill Biopharma commences Phase III trial of RHB-105 to treat H. pylori infection

Deals this week: Vertos Medical, Kiadis Pharma, Oxis International

Vertos Medical has closed a venture financing to raise $28m from MVM Life Science Partners, Leerink Revelation Partners, Pitango Venture Capital, ONSET Ventures and Aweida Venture...

Deals this week: Vertos Medical, Kiadis Pharma, Oxis International

Janssen reports positive long-term results from Phase III trial of sirukumab for RA

Janssen-Cilag International (Janssen) has reported positive long-term results from the Phase III SIRROUND-T clinical trial of sirukumab to treat patients with rheumatoid arthritis...

Janssen reports positive long-term results from Phase III trial of sirukumab for RA
cachename:Newscachekey:rd-1665407042_1857678299_rd-488908060_1460672566_rd1460672566_371857150_ap1460672566_1857678299_1016278895